BALNEOL-HC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BALNEOL-HC (BALNEOL-HC).
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
| Metabolism | Hepatic metabolism via CYP3A4 to inactive metabolites; excreted renally and in feces. |
| Excretion | Primarily renal excretion of metabolites; <10% unchanged. Biliary/fecal elimination is negligible. In children undergoing whole-body application, percutaneous absorption can lead to systemic excretion of hydrocortisone metabolites. |
| Half-life | Hydrocortisone: terminal half-life ~1.5–2.5 hours. With BALNEOL-HC (emollient + hydrocortisone 0.5%), systemic absorption after topical use is minimal (~2–5%), but prolonged application to damaged skin may increase systemic exposure, slightly prolonging half-life. |
| Protein binding | Hydrocortisone: ~90–95% bound to corticosteroid-binding globulin (CBG) and albumin. At high doses, CBG becomes saturated, increasing free fraction. |
| Volume of Distribution | Hydrocortisone: Vd ~0.4–0.6 L/kg. With topical BALNEOL-HC, systemic absorption is low, so effective Vd for absorbed fraction follows that of hydrocortisone; Vd does not change meaningfully. |
| Bioavailability | Topical: Percutaneous absorption is ~2–5% of the applied dose through intact skin, but can increase to 10–30% with occlusive dressings or inflamed/denuded skin. Oral bioavailability of hydrocortisone is ~96%, but not relevant for this topical product. No other routes are indicated. |
| Onset of Action | Topical: Improvement in pruritus and inflammation typically begins within 4–6 hours after first application, but maximal effect may require 2–3 days of regular use. |
| Duration of Action | Duration of effect after a single topical application is approximately 8–12 hours, requiring twice-daily application for sustained control. Duration is prolonged on intact skin versus disrupted skin. |
Apply a thin layer to affected skin areas twice daily. For adult use, 1% hydrocortisone (as BALNEOL-HC) topical application.
| Dosage form | LOTION |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Use lowest potent topical corticosteroid for shortest duration. For children >2 years: apply sparingly to affected area once or twice daily. Not recommended for diaper dermatitis or prolonged use. |
| Geriatric use | Use with caution; apply minimal amount for shortest duration due to increased skin atrophy risk. Avoid occlusive dressings. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BALNEOL-HC (BALNEOL-HC).
| Breastfeeding | Topical hydrocortisone is poorly absorbed; minimal excretion into breast milk is expected. No M/P ratio available. Use low-potency formulations on small areas for short term. Avoid application to breasts or areolae to prevent infant ingestion. Considered compatible with breastfeeding. |
| Teratogenic Risk | Topical corticosteroids are generally considered low risk for teratogenicity when used at recommended doses. However, systemic absorption may increase with extensive use, high potency, or prolonged application. First trimester: Potential but not well-established risk of orofacial clefts from systemic corticosteroids; avoid high potency formulations. Second and third trimesters: No confirmed increased risk of major malformations; risk of fetal growth restriction and adrenal suppression with prolonged high-dose use. Advise minimal use of low-potency agents. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to any component of the formulation","Untreated bacterial, fungal, viral, or parasitic skin infections","Perioral dermatitis","Rosacea"]
| Precautions | ["Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria.","Local adverse reactions include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration, secondary infection, skin atrophy, striae, and miliaria.","May mask signs of infection; use with caution in patients with impaired circulation.","Not for ophthalmic use.","Use in pediatric patients may cause more pronounced HPA axis suppression due to higher skin surface-to-body weight ratio."] |
| Food/Dietary | No known food interactions. However, patients with severe skin conditions may require dietary modifications (e.g., hypoallergenic diet) if suspicion of food allergy. No evidence of direct food-drug interactions with BALNEOL-HC. |
Loading safety data…
| Fetal Monitoring | No specific fetal monitoring required for topical use. For extensive or prolonged use, monitor maternal adrenal suppression signs. Assess fetal growth if high-potency or large-area use occurs. Neonates may require evaluation for adrenal suppression if maternal use was high-dose near term. |
| Fertility Effects | No known impact on fertility from topical hydrocortisone use. Systemic corticosteroids may affect menstrual cycles and spermatogenesis but at typical topical doses, no adverse effects on fertility are reported. |
| Clinical Pearls | BALNEOL-HC is a combination of hydrocortisone and balneol (a mineral oil-based emollient). It is used for inflammatory skin conditions with dryness. The emollient enhances steroid penetration. Limit use to ≤2 weeks on the face or intertriginous areas to avoid atrophy. Avoid use with other topical steroids to prevent cumulative effects. |
| Patient Advice | Apply a thin layer to affected areas only; do not use on broken or infected skin. · Do not cover with bandages or diapers unless directed by your doctor. · Avoid contact with eyes, mouth, or open wounds: rinse with water if accidental contact occurs. · Do not use for more than 2 weeks without re-evaluation, especially on the face or groin. · Discontinue if irritation, rash, or signs of infection (redness, swelling, pus) develop. · Keep out of reach of children; do not use on children under 2 years without medical advice. |